Mavorixafor
- Generic Name
- Mavorixafor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27N5
- CAS Number
- 558447-26-0
- Unique Ingredient Identifier
- 0G9LGB5O2W
- Background
Mavorixafor is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including m...
- Indication
Investigated for use/treatment in HIV infection.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06056297
- Locations
- π¬πͺ
LTD "Israeli-Georgian Medical Research Clinic Healthycore", Tbilisi, Georgia
π¬πͺLEPL The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia
πͺπΈHospital Universitario Son Espases, Mallorca, Spain
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Conditions
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04274738
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMass General Hospital Cancer Center, Boston, Massachusetts, United States
π¬π·University of Athens, Athens, Greece
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT04154488
- Locations
- πΊπΈ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Washington, Seattle, Washington, United States
πΊπΈUSF Health Department of Pediatrics, Saint Petersburg, Florida, United States
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03995108
- Locations
- π¦πΊ
Wesley Hospital, Auchenflower, Queensland, Australia
ππΊUniversity of Debrecen, Affiliated Department of Infectology, Debrecen, Hajdu-Bihar, Hungary
π«π·CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique, Lyon, Rhne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.